Home›Triazole

Triazole

3 interactions on record

Triazole has 3 known drug interactions based on U.S. FDA drug labeling data. Notable interactions include combinations with Artemether And Lumefantrine. Patients taking Triazole should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 3
Moderate: 1
Minor: 1

Moderate (1)

Triazole + Artemether And Lumefantrine— 7.8 Interaction With Drugs That are Known to Prolong the QT Interval Coartem Tablets are to be used with caution when co…

Minor (1)

Triazole + Nefazodone Hydrochloride— Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels…

Triazole + Artemether And Lumefantrine🟡Moderate

7.8 Interaction With Drugs That are Known to Prolong the QT Interval Coartem Tablets are to be used with caution when coadministered with drugs that may cause prolonged QT interval such as antiarrhythmics of Classes IA and III, neuroleptics and antidepressant agents, certain antibiotics including some agents of the following classes: macrolides, fluoroquinolones, imidazole, and triazole antifungal agents [see Warnings and Precautions (5.1, 5.2)] .

Triazole + Nefazodone Hydrochloride🟢Minor

Similarly, there were no changes in the pharmacokinetic parameters of nefazodone or HO-NEF; however, the mean AUC levels of the nefazodone metabolites mCPP and triazole-dione increased by 3 to 6 fold and 1.3 fold, respectively. There were also no changes in the pharmacokinetics of nefazodone or its triazole-dione metabolite, but the AUC and C max of mCPP increased by 44% and 48%, respectively, while the AUC of HO-NEF decreased by 19%. When the two drugs were coadministered, there were no changes in the steady-state pharmacokinetics of either lithium, nefazodone, or its metabolite HO-NEF; however, there were small decreases in the steady-state plasma concentrations of two nefazodone metabolites, mCPP and triazole-dione, which are considered not to be of clinical significance.

Triazole + Fexinidazoleℹ️Unknown

Drugs that May Prolong the QT Interval and/or Induce Bradycardia Coadministration of Fexinidazole Tablets with drugs known to block potassium channels (e.g., antiarrhythmics, neuroleptics, fluoroquinolones, imidazole and triazole antifungals, pentamidine) prolong the QT interval (e.g., antimalarials, phenothiazines, tricyclic antidepressants, terfenadine and astemizole, IV erythromycin, and quinolone antibacterial drugs) and/or induce bradycardia (such as β-blockers) should be avoided [see Warnings and Precautions (5.2) ] .

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.